Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Bacillus subtilis COVID-19 Vaccine Study
NCT05057923Phase 1Completed
- Sponsor
- DreamTec
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of bacillus subtilis in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by DreamTec. Primary endpoint: Serum Neutralizing Receptor Binding Domain IgG Antibody Concentration at Day 42. Started Jul 2021; status: completed.
02
Drugs
bacillus subtilis
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05057923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057923.